Biotech Patent Drafting Guide: Sequence Listings and Deposit Requirements

Biotechnology inventions, by their very nature, often involve complex biological materials such as DNA, RNA, amino acid sequences, and microorganisms. Protecting these innovations through patents demands specialized drafting techniques that go beyond conventional mechanical or software inventions. Two paramount aspects in biotech patent drafting are the proper handling of sequence listings and the fulfillment of biological deposit requirements. Failure to comply with these can lead to significant delays, rejections, or even the invalidation of an otherwise valuable patent.

The Evolution of Sequence Listings: From ST.25 to WIPO ST.26

For decades, the global standard for presenting nucleotide and amino acid sequences in patent applications was WIPO Standard ST.25. However, with the rapid advancements in bioinformatics and sequencing technologies, ST.25 began to show its limitations, particularly in handling newer sequence types and large datasets. This led to the development and implementation of WIPO Standard ST.26, which became mandatory for all international (PCT) and national patent applications filed on or after July 1, 2022.

Key Insight: The transition from ST.25 to ST.26 is not merely a cosmetic change; it's a fundamental shift designed to improve data accuracy, machine readability, and global harmonization for biotechnology sequence listings. Patent applicants must ensure their sequence listings are fully compliant with ST.26.

What's New in ST.26?

The changes introduced by ST.26 are significant and impact how biotech patent attorneys and inventors prepare their applications:

1. XML Format: ST.26 mandates the use of an XML (eXtensible Markup Language) file format. This allows for structured, machine-readable data, facilitating automated processing and database integration by patent offices worldwide. In contrast, ST.25 used a less structured text format.
2. Expanded Scope of Sequence Types: ST.26 covers a broader array of sequence types, including:
   • Modified Nucleotides and Amino Acids: ST.25 struggled with representing modified bases or residues. ST.26 provides specific mechanisms for their annotation.
   • D-amino acids: Now explicitly supported.
   • Branched sequences: While still challenging, ST.26 offers better frameworks.
   • Nucleic acid analogs: More robust handling.
   • Disclosures of "ranges" of sequences: ST.26 requires the disclosure of the specific sequence within the range if it's considered part of the invention.
3. Mandatory Feature Keys and Qualifiers: ST.26 heavily relies on a comprehensive set of feature keys and qualifiers to describe specific regions, functions, or characteristics of a sequence. For instance, a "CDS" (coding sequence) feature key would be used, along with qualifiers like "/translation" to show the corresponding protein. This structured annotation enhances the clarity and searchability of the sequence data.
4. Checksums: ST.26 files include checksums to ensure data integrity during transmission and storage.
5. No More "Small" Sequences in the Main Description: Under ST.25, short sequences (e.g., primers) could be included directly in the patent specification. ST.26 generally requires all disclosed sequences to be part of the ST.26 sequence listing, unless they are extremely short (e.g., 4 or fewer nucleotides, or 10 or fewer amino acids, used as general formulae rather than specific sequences).
6. Specific Software for Creation: WIPO provides a free software tool, "WIPO Sequence," to assist applicants in creating ST.26-compliant sequence listings. Using this tool is highly recommended to avoid technical errors.

Practical Implications for Biotech Patent Drafting

• Early Adoption: Even if your national office had a grace period, for international filings, ST.26 is the rule. Begin drafting with ST.26 compliance in mind from day one.
• Data Preparation: Organize your sequence data meticulously. Ensure you have all necessary annotations (e.g., organism, molecule type, features, modifications) ready for input into WIPO Sequence.
• Training: Patent professionals and inventors involved in biotech need to be trained on the nuances of ST.26 and WIPO Sequence software.
• Consistency: The sequences in the ST.26 file must be entirely consistent with the sequences described in the main body of the patent application. Discrepancies can lead to objections regarding lack of support or new matter.

Biological Deposit Requirements: The Budapest Treaty

Many biotechnology inventions involve biological materials that cannot be adequately described in words, figures, or sequence listings alone. Examples include novel microorganisms (bacteria, fungi, viruses), cell lines, plasmids, and vectors. To ensure that these inventions can be reproduced by others, as required by patent law's enablement provision, patent offices often mandate the deposit of biological material at a recognized depository institution.

The Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure, signed in 1977, simplifies this process significantly. Prior to the treaty, an applicant might have to deposit the same microorganism in every country where they sought patent protection, leading to substantial costs and logistical nightmares.

Statistics: As of early 2023, the Budapest Treaty has 89 contracting states, including major patent jurisdictions like the United States, Europe (EPO), Japan, China, India, and South Korea. This widespread adoption underscores its importance in global biotech patenting.

Key Aspects of the Budapest Treaty

1. Single Deposit, Global Recognition: The core principle is that a single deposit of a microorganism with any "International Depositary Authority" (IDA) under the Budapest Treaty is sufficient for patent purposes in all contracting states. This eliminates the need for multiple deposits.
2. International Depositary Authorities (IDAs): These are scientific institutions (e.g., culture collections) designated by WIPO as meeting specific standards for accepting, storing, and furnishing biological material. There are currently 48 IDAs located in various countries.
3. Viability and Storage: IDAs are responsible for maintaining the viability of the deposited material for at least 30 years from the date of deposit, or for 5 years after the most recent request for a sample, whichever is later.
4. Furnishing of Samples: The IDA will furnish samples of the deposited material to "legitimately interested parties" (e.g., patent offices, or third parties authorized by the patent office or the depositor) under specific conditions, typically after the patent application is published.
5. Deposit Date: The date of deposit is crucial as it establishes the availability of the biological material for enablement purposes. It's often advisable to deposit the material before filing the patent application, or at least concurrently.
6. Information to Provide: When making a deposit, the applicant must provide:
   • The biological material itself.
   • A scientific description of the material.
   • Information on its characteristics and viability.
   • Safety information.

When is a Deposit Required?

A deposit is generally required when:

• The biological material is not publicly available (e.g., not commercially available, not part of a publicly accessible collection).
• The biological material cannot be adequately described in the patent application to enable a person skilled in the art to reproduce it without undue experimentation. This is the "enablement" standard.

Case Study: In re Argoudelis (1970, US Court of Customs and Patent Appeals): This landmark U.S. case established the precedent for requiring a deposit of microorganisms when written description alone is insufficient for enablement. The court held that if a microorganism is essential to the invention and cannot be reasonably reproduced from the written description, a deposit is necessary. This principle underpins deposit requirements in many jurisdictions.

Practical Guidance for Deposits

• Plan Ahead: Identifying the need for a deposit and selecting an IDA should be done early in the invention disclosure process. The deposit process can take time.
• Select an IDA: Consider geographical location, expertise with your specific biological material, and cost when choosing an IDA.
• Obtain an Accession Number: Once the deposit is accepted, the IDA will issue an accession number. This number must be included in the patent application.
• Referencing in the Application: The patent application must clearly state that a deposit has been made, provide the IDA's name, and the accession number. For example: "The microorganism Escherichia coli strain XYZ-1 was deposited under the terms of the Budapest Treaty at the American Type Culture Collection (ATCC) on [Date] and assigned accession number PTA-12345."
• Viability Statement: Some patent offices (e.g., USPTO) require a statement confirming the viability of the deposited material.

Drafting Gene Patent Claims: Specificity and Scope

Gene patents, while facing scrutiny and limitations in some jurisdictions (e.g., Association for Molecular Pathology v. Myriad Genetics, Inc. in the US, which held isolated genomic DNA unpatentable), remain a critical area, especially for synthetic DNA, cDNA, modified genes, and methods utilizing genes. Drafting claims for these inventions requires precision.

Key Considerations for Gene Patent Claims:

1. Sequence Identity: Claims often define sequences by their identity to a reference sequence. For example: "An isolated polynucleotide comprising a sequence having at least 90% identity to SEQ ID NO: 1."
   • Percentage Identity: Specify the percentage (e.g., 70%, 80%, 90%, 95%, 98%, 99%).
   • Method of Determination: If specific algorithms (e.g., BLAST) and parameters (e.g., gap penalties) are crucial for determining identity, they should be mentioned.
2. Functional Limitations: Beyond mere sequence identity, incorporating functional limitations can strengthen claims, particularly for modified or synthetic sequences.
   • "wherein said polynucleotide encodes a protein having [specific enzymatic activity]."
   • "wherein said polynucleotide is capable of hybridizing under stringent conditions to SEQ ID NO: 2."
3. "Isolated" vs. "Naturally Occurring": For nucleic acids, the term "isolated" is critical to distinguish the claimed invention from naturally occurring sequences within an organism. The Myriad decision emphasized that merely isolating a natural product does not create a patentable invention in the US. However, cDNA, synthetic sequences, and methods of use remain patentable.
4. Vector and Host Cell Claims:
   • "A recombinant expression vector comprising the polynucleotide of claim X operably linked to a promoter."
   • "A host cell transformed with the recombinant expression vector of claim Y."
5. Method Claims:
   • Methods of Use: "A method for producing [protein] comprising culturing the host cell of claim Z under conditions suitable for expression."
   • Methods of Treatment: "A method for treating [disease] comprising administering a therapeutically effective amount of the protein encoded by the polynucleotide of claim X."
   • Diagnostic Methods: These can be challenging in some jurisdictions (e.g., US), requiring careful drafting to avoid claiming natural laws or abstract ideas. Focus on specific, inventive steps.
6. Markush Claims for Variants: When a family of related sequences is covered, a Markush group can be used, e.g., "A polynucleotide comprising a sequence selected from the group consisting of SEQ ID NO: 1, a sequence having at least 95% identity to SEQ ID NO: 1 and encoding a protein with [function], and a fragment of SEQ ID NO: 1 of at least 20 nucleotides that hybridizes under stringent conditions to SEQ ID NO: 1."

Practical Tip: When drafting gene patent claims, always consider the interplay between the sequence listing, the written description, and the claims. The claims must be fully supported by the description, and the sequences referenced in the claims must be present in the ST.26 compliant sequence listing.

Conclusion

Biotechnology patent drafting is a highly specialized field that demands a deep understanding of scientific principles, legal requirements, and international standards. Adherence to WIPO ST.26 for sequence listings and compliance with the Budapest Treaty for biological deposits are not mere bureaucratic hurdles but essential steps to ensure the validity and enforceability of your biotech patents. By mastering these requirements, innovators can secure robust protection for their groundbreaking inventions, fostering continued progress in the life sciences.

Frequently Asked Questions

Q1: What is the main difference between WIPO ST.25 and ST.26 sequence listings?

A1: The primary difference lies in the format and scope. ST.25 used a less structured text format, while ST.26 mandates an XML file format, making it machine-readable and more structured. ST.26 also supports a broader range of sequence types (e.g., modified nucleotides/amino acids, D-amino acids) and requires more detailed feature annotations, improving data accuracy and searchability.

Q2: When is a biological deposit under the Budapest Treaty necessary for a patent application?

A2: A deposit is generally necessary when the biological material central to the invention (e.g., a novel microorganism, cell line) is not publicly available and cannot be adequately described in the written patent application to enable a person skilled in the art to reproduce it without undue experimentation. The Budapest Treaty allows a single deposit to be recognized in all contracting states, simplifying international patenting.

Q3: Can I still get a patent for a gene sequence after the Myriad decision in the US?

A3: Yes, but with important distinctions in the US. The Myriad decision held that isolated naturally occurring genomic DNA is not patentable subject matter. However, synthetic DNA (e.g., cDNA), modified gene sequences, recombinant DNA constructs, and methods of using genes (e.g., diagnostic methods, therapeutic methods, methods for producing proteins) generally remain patentable if they meet other patentability criteria (novelty, non-obviousness, utility, enablement, written description). Other jurisdictions may have different interpretations.

Q4: What information must be included in a patent application if a biological deposit has been made?

A4: The patent application must clearly state that a deposit has been made, identify the International Depositary Authority (IDA) where the material was deposited, and provide the official accession number assigned to the deposit. It's also good practice to include the date of deposit and, in some jurisdictions, a statement confirming the viability of the deposited material.